Health
DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
TOKYO & BASKING RIDGE, N.J., October 17, 2025--Initial results from one sub-study of the TROPION-PanTumor03 phase 2 trial showed that DATROWAY® (datopotamab deruxtecan) plus rilvegostomig showed promising tumor responses and disease control as first-line and second-line combination therapy in patients with locally advanced or metastatic urothelial cancer. These results were presented today as a mini oral session (3072MO) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/147724fa27f28411a25beb6c72cd5a54"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zyIlzkClFgK.21CUIrMz1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/147724fa27f28411a25beb6c72cd5a54","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in combination with rilvegostomig in previously untreated, cisplatin ineligible patients","length":229,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TROPION-Urothelial03 phase 2/3 trial initiated to further evaluate the role of DATROWAY plus platinum-based chemotherapy in previously treated metastatic urothelial cancer","length":171,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":400,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., October 17, 2025--(BUSINESS WIRE)--Initial results from one sub-study of the TROPION-PanTumor03 phase 2 trial showed that DATROWAY® (datopotamab deruxtecan) plus rilvegostomig showed promising tumor responses and disease control as first-line and second-line combination therapy in patients with locally advanced or metastatic urothelial cancer. These results were presented today as a mini oral session (3072MO) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.","length":515,"tagName":"p"},{"type":"text","content":"DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). Rilvegostomig is AstraZeneca’s PD-1/TIGIT bispecific antibody.","length":294,"tagName":"p"},{"type":"text","content":"In a sub-study of patients with locally advanced or metastatic urothelial cancer, DATROWAY plus rilvegostomig was evaluated in both the first-line and second-line treatment settings. As first-line treatment for patients not eligible for cisplatin (n=22), DATROWAY plus rilvegostomig demonstrated ...